Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial
European Journal of Neurology · 2025
DOI: 10.1111/ene.16420 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Joaquim J Ferreira und 9 weiteren Autor:innen. Beteiligte Einrichtung: IMM - Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade Lisboa, Lisbon, Portugal. Hauptthemen laut MEDLINE: Antiparkinson Agents, Drug Therapy, Combination, Levodopa, Parkinson Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Catechol‐O‐methyl transferase (COMT) inhibitors are routinely used to manage motor fluctuations in Parkinson's disease (PD). We assessed the effect of opicapone on motor symptom severity in levodopa‐treated patients without motor complications.
Methods
This was a randomized, double‐blind, 24‐week, placebo‐controlled study of opicapone 50 mg as adjunct to levodopa (NCT04978597). Levodopa‐treated patients without motor complications were randomized to 24 weeks of double‐blind treatment with adjunct opicapone 50 mg or matching placebo. The primary efficacy endpoint was the mean change from baseline to week 24 in Movement Disorder Society‐Unified Parkinson's Disease Rating Scale Part III (MDS‐UPDRS‐III) total score.
Results
A total of 355 patients were randomized (opicapone 50 mg n = 177, placebo n = 178) and 322 (91%) completed the double‐blind period. The adjusted mean [95% CI] change from baseline to week 24 in MDS‐UPDRS‐III subscore was −6.5 [−7.9, −5.2] in the opicapone group versus −4.3 [−5.7, 3.0] in the placebo group resulting in a significant difference of −2.2 [−3.9, −0.5] favoring opicapone ( p = 0.010). There was no difference in the incidence of patients who developed motor complications (5.5% with opicapone vs. 9.8% with placebo) and the incidence of adverse events considered related to study medication was similar between groups (opicapone 10.2% vs. placebo 13.5%).
Conclusions
Treatment with once‐daily adjunct opicapone was well tolerated, improved motor severity, and did not induce the development of motor complications. These results support the clinical usefulness of opicapone in the management of PD patients without motor complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IMM - Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade Lisboa, Lisbon, Portugal.
- CNS - Campus Neurológico, Torres Vedras, Portugal.
- Clinical Investigation Centre CIC1436, Department of Neurosciences and Clinical Pharmacology, Centre of Excellence for Neurodegeneration COEN NeuroToul, and NS-Park/FCRIN Network, University of Toulouse 3, University Ho…
- University San Raffaele Roma and Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy.
- Parkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padua, Padua, Italy.
- BIAL - Portela & Ca S.A, Coronado, Portugal.
ORCID-Profile: Fabrizio Stocchi, José-Francisco Rocha
Zitieren
APA
Ferreira, J. J., Rascol, O., Stocchi, F., Antonini, A., Moreira, J., Castilla-Fernández, G., Rocha, J. F., Holenz, J., Poewe, W., & Epsilon Study investigators (2025). Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial. European Journal of Neurology. https://doi.org/10.1111/ene.16420
Vancouver
Ferreira JJ, Rascol O, Stocchi F, Antonini A, Moreira J, Castilla-Fernández G, et al. Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial. European Journal of Neurology. 2025. doi:10.1111/ene.16420
BibTeX
@article{Ferreira2025,
author = {Ferreira, Joaquim J and Rascol, Olivier and Stocchi, Fabrizio and Antonini, Angelo and Moreira, Joana and Castilla-Fernández, Guillermo and Rocha, José-Francisco and Holenz, Joerg and Poewe, Werner and Epsilon Study investigators, Epsilon Study investigators},
title = {Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.16420}
}
EUVIMED